Patents Assigned to LTS Lohmann
-
Publication number: 20200330434Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound that includes: a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, one or more dicarboxylic acids, 0.5 to 10.0 wt.-% (based on the total weight of the composition) of one or more monocarboxylic acids, and water or an aqueous solvent mixture. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.Type: ApplicationFiled: December 13, 2018Publication date: October 22, 2020Applicant: LTS Lohmann Therapie-Systeme AGInventors: Michael LINN, Christoph SCHMITZ, Hanshermann FRANKE
-
Patent number: 10806703Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.Type: GrantFiled: January 20, 2012Date of Patent: October 20, 2020Assignees: LTS Lohmann Therapie-System AG, Santhera Pharmaceuticals (Schweitz) AGInventors: Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
-
Publication number: 20200323787Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound. The inventive compositions include a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, a dicarboxylic acid, and water or an aqueous solvent mixture, with the composition being free of monocarboxylic acids. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.Type: ApplicationFiled: December 13, 2018Publication date: October 15, 2020Applicant: LTS Lohmann Therapie-Systeme AGInventors: Michael LINN, Christoph SCHMITZ, Hanshermann FRANKE
-
Publication number: 20200316055Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.Type: ApplicationFiled: June 18, 2020Publication date: October 8, 2020Applicant: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Thomas Hille, Gabriel Wauer, Frank Seibertz, Shu-Lun Weinheimer
-
Publication number: 20200306204Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) e a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contactType: ApplicationFiled: January 31, 2020Publication date: October 1, 2020Applicant: LTS Lohmann Therapie-Systeme AGInventors: Thomas Hille, Gabriel Wauer, Kevin John Smith, Helen Elizabeth Johnson, Gillian Elizabeth Mundin
-
Patent number: 10772845Abstract: The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.Type: GrantFiled: December 2, 2010Date of Patent: September 15, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventors: Michael Horstmann, Horst Dzekan, Sandra Wiedersberg
-
Patent number: 10744176Abstract: An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.Type: GrantFiled: July 15, 2019Date of Patent: August 18, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventors: Michael Li, Markus Krumme
-
Publication number: 20200253957Abstract: The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-contaType: ApplicationFiled: April 30, 2020Publication date: August 13, 2020Applicant: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Gabriel Wauer, Thomas Hille, Kevin John Smith, Gillian Elizabeth Mundin, Helen Elizabeth Johnson
-
Publication number: 20200237748Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.Type: ApplicationFiled: April 9, 2020Publication date: July 30, 2020Applicant: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Thomas Hille, Gabriel Wauer, Frank Seibertz, Shu-Lun Weinheimer
-
Patent number: 10716762Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.Type: GrantFiled: January 17, 2013Date of Patent: July 21, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventors: Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
-
Patent number: 10709669Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.Type: GrantFiled: October 15, 2019Date of Patent: July 14, 2020Assignee: LTS LOHMANN Therape-Systeme AGInventor: Walter Müller
-
Patent number: 10653636Abstract: A medical active substance patch comprising a matrix of monolayer or multilayer configuration with at least one active substance-containing layer and comprising a backing layer connected with the matrix. The active substance patch is transparent or at least translucent, and in the state of having been applied to the skin of a first person, the patch has a lightness colour value L1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness colour value L2, L2 being the lightness value of the region of the skin of the same person which surrounds the applied patch. The same is true of the skin of a second or any other person, provided that for all the persons mentioned L2 is in the range from 5° to 100°, namely from 20° to 90°.Type: GrantFiled: April 8, 2004Date of Patent: May 19, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventor: Stefan Bracht
-
Patent number: 10646453Abstract: A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value L1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L2, with L2 being the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the L2 of their respective skin is in the range from 5° to 100°, especially in the range from 20° to 90°.Type: GrantFiled: February 1, 2019Date of Patent: May 12, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventor: Stefan Bracht
-
Patent number: 10596126Abstract: The present invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.Type: GrantFiled: April 10, 2019Date of Patent: March 24, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventors: Michael Horstmann, Mohammad Sameti, Tobias Jung
-
Patent number: 10583093Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.Type: GrantFiled: January 31, 2019Date of Patent: March 10, 2020Assignee: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Walter Müller, Thomas Hille
-
Publication number: 20200071571Abstract: A method of inverting the phase arrangement of the silicone phase and the acrylic phase in a silicone acrylic hybrid composition, the silicone acrylic hybrid composition comprising: a) a silicone acrylic hybrid pressure sensitive adhesive, and b) a solvent, wherein the phase arrangement of the silicone phase and the acrylic phase in the initial silicone acrylic hybrid composition forming a continuous external phase and a discontinuous internal phase is determined by the solvent, comprising the step of adding an activator to the silicone acrylic hybrid composition, wherein the activator a) is liquid at 20° C. and 1013 mbar, b) has a boiling point which is higher than the boiling point of the solvent and/or has a vapor pressure at 20° C.Type: ApplicationFiled: July 19, 2017Publication date: March 5, 2020Applicants: LTS LOHMANN Therapie-Systeme AG, Dow Silicones CorporationInventor: Marco EMGENBROICH
-
Patent number: 10568845Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.Type: GrantFiled: July 10, 2002Date of Patent: February 25, 2020Assignee: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Walter Müller, Thomas Hille
-
Patent number: 10532033Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.Type: GrantFiled: April 29, 2004Date of Patent: January 14, 2020Assignee: LTS LOHMANN Therapie-Systeme AGInventor: Walter Müller
-
Publication number: 20190365662Abstract: The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).Type: ApplicationFiled: January 17, 2017Publication date: December 5, 2019Applicant: LTS Lohmann Therapie-Systeme AGInventors: Florian HAMMES, René EIFLER
-
Patent number: 10485967Abstract: The invention relates to a transdermal therapeutic system (TTS) for delivering pharmaceutical active ingredients. The TTS includes a cover layer and at least one active-ingredient-containing carrier material. At least one retaining element is located between the active-ingredient-containing carrier material and the cover layer, with the retaining element fixing the active-ingredient-containing carrier material onto the cover layer. The invention further relates to a method for fastening an active-ingredient-containing carrier material to a cover layer of a TTS in the presence of hook-and-loop strip segments and the use of a hook-and-loop strip in transdermal or iontophoretic administration of pharmaceutical or therapeutic active ingredients to patients.Type: GrantFiled: December 17, 2014Date of Patent: November 26, 2019Assignee: LTS Lohmann Therapie-Systeme AGInventors: Mohammad Sameti, Ronald Hackbarth, Klaus Schumann, Christoph Schmitz